Compare Visa Inc (V) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Visa Inc vs GeneDx Holdings Corp — how do they compare? Visa Inc trades at $361.98 (market cap $671.74B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.44B). The key difference: Visa Inc is far larger — about 275.3× GeneDx Holdings Corp's market cap, and Visa Inc pays a 0.74% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| V | WGS | |
|---|---|---|
Market Cap | $671.74B | $2.44B |
Volume | 10,431,336 | — |
Sector | Financials | Technology |
52-Week High | $370.47 | $167.51 |
52-Week Low | $295.52 | $34.51 |
Enterprise Value | $682.32B | $2.48B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals including a 50.78% net income margin and consistent earnings beats. Recent news highlights AI-driven commerce initiatives and stablecoin partnerships, positioning the company for future growth. The stock is near its pivot point of $361, with support at $359 and resistance at $364.
The outlook remains positive with an 85% analyst buy rating and a $426.31 consensus price target, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and high profitability support long-term value. The next earnings report on April 28, 2026, will be a key catalyst.
GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.
Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
